The landmark Randomized Aldactone Evaluation Study (RALES), published in 1999, showed that spironolactone, a potassium-sparing diuretic, improves outcomes in patients with severe heart failure.

During the open-label run-in period, patients underwent spironolactone titration, with a target to 50 mg/daily, and those with hyperkalemia started SZC. Patients with normokalemia (potassium 3.5-5 ...

Using patient kidney biopsies, the team developed a new method to measure glycocalyx thickness, confirming that the layer is ...

Estimated glomerular filtration rate decreased in both groups, but the average decrease after 1 year was greater in the spironolactone group (P = 0.004). Increases in serum potassium levels ...

The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...

Talk with your doctor before taking any other medications while taking spironolactone. That includes nutritional supplements (especially potassium) and diuretics. Before taking spironolactone ...

Only 6.5% of patients taking drospirenone and spironolactone had a serum potassium assay within 180 days of starting concomitant therapy. Conclusions: A clinically significant signal for ...

It has some similarities to the potassium-sparing diuretic spironolactone, but rarely causes gynecomastia. It had been approved for hypertension. The new FDA labeling provides "for improving ...

Aldosterone antagonists (spironolactone, eplerenone) also known as “potassium sparing diuretics” block the action of aldosterone inhibiting the reuptake of sodium and water. Normally ...